Altogether, our data clearly reveal that PD-1 signaling leads to a less prominent Th2 profile in pulmonary ILC2s and suggest that a specific agonist of PD-1 could be a potential therapeutic strategy in ILC2-dependent asthma. The gene discussed is PDCD1; the disease is asthma.